Jefferies Downgrades Nektar Therapeutics to Underperform, Lowers Price Target to $1.5
Jefferies analyst Roger Song downgrades Nektar Therapeutics (NASDAQ:NKTR) from Hold to Underperform and lowers the price target from $3.2 to $1.5.
Stocks That Hit 52-Week Lows On Tuesday
Tuesday's session saw 325 companies set new 52-week lows.
Stocks That Hit 52-Week Lows On Thursday
Thursday's session saw 329 companies set new 52-week lows.
Stocks That Hit 52-Week Lows On Friday
During Friday's trading, 293 companies set new 52-week lows.
Nektar Announces Poster Presentations At The 64th American Society Of Hematology Annual Meeting
-- Unveils Trial Design for Nektar Phase 2/3 Study Combining NKTR-255 with CAR-T Therapies --
-- Presents First Data for NKTR-255 in Combination with Daratumumab in Patients with Relapsed/Refractory Multiple
Stocks That Hit 52-Week Lows On Wednesday
During Wednesday's session, 107 stocks hit new 52-week lows.
Analyst Says IO Biotech’s Cancer Treatment Approach ‘Differentiated’
HC Wainwright has initiated coverage on Denmark-based cancer firm IO Biotech Inc (NASDAQ:IOBT) with a Buy rating and a price target of $10.…